Serum bcl-2 and survivin levels in melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 543-546

  Tas, Faruk ^a   Duranyildiz, Derya ^a   Argon, Andac ^a   Oguz, Hilal ^a   Camlica, Hakan ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anti apoptosis; Apoptosis; bcl 2; Melanoma; Serum; Survivin

Indexed keywords

ALPHA2B INTERFERON; CYTOTOXIC AGENT; DACARBAZINE; FLUORESCEIN ISOTHIOCYANATE; HORSERADISH PEROXIDASE; LACTATE DEHYDROGENASE; PROTEIN BCL 2; SURVIVIN;

ADULT; AGE; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SERUM; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DACARBAZINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 13544254561     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00017     Document Type: Article

References (22)

1. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6:127-134.
2. Garcia I, Martinou I, Tsujimoto Y, Martinou JC. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 1992; 258:302-304.
3. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogens 1994; 9:3367-3370.
4. Ben-Ezra JM, Kornstein MJ, Grimess MM, Krystal G. Small-cell carcinoma of the lung expresses the Bcl-2 protein. Am J Pathol 1994; 145:1036-1040.
5. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgene-independent prostate cancer. Cancer Res 1992; 52:6940-6944.
6. Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4:1865-1871.
7. Selzer E, Schagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998; 8:197-203.
8. LaCasse EC, Baird S, Korneluk RG, Mackenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17:3247-3259.
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-921.
10. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-5074.
11. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002; 184: 105-116.
12. Pizem J, Cör A. Survivin - an inhibitor of apoptosis and a new therapeutic target in cancer. Radiol Oncol 2003; 37:195-201.
13. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076-1081.
14. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003; 21:306-312.
15. Morales-Ducret C, van de Rijn M, LeBrun DP, Smoller BR. Bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131:909-912.
16. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000; 292:225-232.
17. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2 expression in benign versus malignant components. J Cutan Med Surg 1999; 3:293-297.
18. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21(1):43-52.
19. Gradilone A, Greco C, Gazzaniga P, Vercillo R, Napolitano M, Gandini O, et al. BAX gene expression in melanoma metastases. J Invest Dermatol 1996; 106:382.
20. Mecchia M, Matarrese P, Malorni W, D'Agostino G, Sestili P, Santini SM, et al. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha. Gene Ther 2000; 7:167-179.
21. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8:17-23.
22. Grossman D, Altieri D. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metas Rev 2001; 20:3-11.